EGFR and neoplasm: The anti-EGFR nanobody D10 has an affinity of 7 nM towards human EGFR and does not compete with the binding site of Cetuximab, the approved anti-EGFR antibody for the treatment of different tumour entities such as colorectal or head and neck cancer (SCCHN).